reports
- Hela Zarrouk
Allane SE : Q1 2024 results in line with expectations – 2024 outlook c...
>Q1 2024 results in line with expectations - Allane SE released its final Q1 2024 results which were in line with expectations. In detail, we note:Consolidated revenue (including sales revenue) increased by 16.0% to € 175.5m (Q1 2023: € 151.3m) vs our estimates of € 172.3.Consolidated operating revenue (excl. sales revenue) increased by 32.4% to € 103.8m (ODDO BHF: € 71.9m), mainly driven by an increase in leasing income, more specifically in the Retail Leas...
- Hela Zarrouk
Allane SE : Q1 2024 results in line with expectations – 2024 outlook c...
>Q1 2024 results in line with expectations - Allane SE released its final Q1 2024 results which were in line with expectations. In detail, we note:Consolidated revenue (including sales revenue) increased by 16.0% to € 175.5m (Q1 2023: € 151.3m) vs our estimates of € 172.3.Consolidated operating revenue (excl. sales revenue) increased by 32.4% to € 103.8m (ODDO BHF: € 71.9m), mainly driven by an increase in leasing income, more specifically in the Retail Leas...
- Benoit Valleaux
- Roland Pfaender
- MBA
- CFA
- CCRA
Generali : RN solide attendu au T1
>Forte croissance de l’activité - Generali publiera son RN du T1 2024 le 21 mai prochain. Rappelons que le groupe consolidera pour la 1ère fois Liberty Seguros, dont l’acquisition a été finalisée fin janvier. Nous prévoyons des primes de 23.5 Md€ (+5.8%) légèrement supérieures au consensus (23.0 Md€), avec : 1/ une croissance de 3% des primes en assurance vie, dans un contexte de reprise du marché de l’assurance vie dans certains pays (et notamment en France et en It...
- Baptiste Lebacq
Tecnicas Reunidas : Feuille de route tenue en ce début d’année
>Recommandation Neutre OC relevé à 10 € - Post publication et conférence call, nous avons maintenu notre séquence de BPA 2024/26. Nous relevons notre OC à 10 € (vs 9 €) et réitérons notre recommandation Neutre sur le titre. Le redressement de la marge d’EBIT semble se confirmer et nous réduisons la décote retenue sur les multiples des pairs. A 10 €, le PE implicite ressort à 6.5x soit une décote de près de 50% versus notre échantillon européen (que nous justifio...
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% O...
BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the dermatology business in Europe. Net Sales increased by 6.6% to a total of €247.4 MM, EBITDA was €52.5 MM (increase of 1.4% YoY) driven by higher sales growth, with a gross margin of 63.5%. Dermatology sales in Europe increased by 18.1% to a total of €113MM. Continued strong investments in supporting the Ebglyss laun...
- ABGSC Strategy Research
- Bengt Jonassen
SIG successfully places €450 million Schuldschein following strong dem...
SIG Group AG / Key word(s): Issue of Debt/Issue of Debt SIG successfully places €450 million Schuldschein following strong demand from investors 13.05.2024 / 07:00 CET/CEST MEDIA RELEASE 13 May 2024 SIG successfully places €450 million Schuldschein following strong demand from investors SIG today announces it has successfully completed a €450 million Schuldschein placement. The notes are structured in tranches with maturities of four, five and seven years with both fixed and variable interest rates at competitive levels. The high level of demand from a wide range of invest...
SIG platziert Schuldscheindarlehen in Höhe von EUR 450 Millionen bei s...
SIG Group AG / Schlagwort(e): Anleiheemission/Anleiheemission SIG platziert Schuldscheindarlehen in Höhe von EUR 450 Millionen bei starker Nachfrage von Investoren 13.05.2024 / 07:00 CET/CEST MEDIENMITTEILUNG 13. Mai 2024 SIG platziert Schuldscheindarlehen in Höhe von EUR 450 Millionen bei starker Nachfrage von Investoren SIG hat erfolgreich ein Schuldscheindarlehen in Höhe von EUR 450 Millionen platziert. Die Emission besteht aus drei Tranchen mit Laufzeiten von vier, fünf und sieben Jahren mit festen und variablen Zinssätzen auf einem attraktiven Niveau. Aufgrund der hoh...
Moody's Ratings assigns definitive rating to Auto Loan ABS Program 240...
Moody's Ratings (Moody's) has assigned a definitive rating to the following transaction. The complete rating action is as follows: Transaction Name: Auto Loan ABS Program 2405 Series Class: ABL Rating: Aaa (sf) Issue Amount: JPY398 million Interest Rate: Fixed Closing Date: May 13, 2024 Final Matur...
CTS Global Equity Group Inc: 1 director
A director at CTS Global Equity Group Inc sold 37,000,000 shares at 0.680PHP and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Cemex Holdings Philippines Inc: 1 director
A director at Cemex Holdings Philippines Inc sold 1,300,000 shares at 1.383PHP and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Moody's Ratings assigns definitive rating to Auto Loan ABS Program 240...
1/6NEWSContact:東京 東京齋藤 奈都子 関 雄介主任格付アナリスト／アナリスト 格付責任者／ｱｿｼｴｲﾄ･ﾏﾈｰｼﾞﾝｸﾞ･ﾃﾞｨﾚｸﾀｰストラクチャード・ファイナンス ストラクチャード・ファイナンスムーディーズSFジャパン株式会社 ムーディーズSFジャパン株式会社お客様専用電話番号：03-5408-4210 報道関係者電話番号：03-5408-4220お客様専用電話番号：03-5408-4210 報道関係者電話番号：03-5408-4220[MSFJ]信託提携オートローンプログラム2405シリーズに格付を付与 発行額3.98億円の証券化商品を対象として 2024年5月13日、...
EQS-News: ProCredit startet mit starkem Q1-Ergebnis gut ins neue Gesch...
EQS-News: ProCredit Holding AG / Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung ProCredit startet mit starkem Q1-Ergebnis gut ins neue Geschäftsjahr 13.05.2024 / 06:58 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. ProCredit startet mit starkem Q1-Ergebnis gut ins neue Geschäftsjahr Konzernergebnis von 33,5 Mio. EUR entspricht einer Eigenkapitalrendite von 13,4 % Kreditportfolio wächst um 3,0 % mit gutem Beitrag aus allen Segmenten Wachstum der Einlagen um 2,8 %; Privatkunden als Haupttreiber im Einklang mit der aktu...
EQS-News: Newron veröffentlicht überzeugende zusätzliche Daten, welche...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Studienergebnisse Newron veröffentlicht überzeugende zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen 13.05.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron veröffentlicht überzeugende zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen Weitere Analysen der St...
EQS-News: ProCredit with strong Q1 result and good start into the year
EQS-News: ProCredit Holding AG / Key word(s): Quarter Results/Quarterly / Interim Statement ProCredit with strong Q1 result and good start into the year 13.05.2024 / 06:58 CET/CEST The issuer is solely responsible for the content of this announcement. ProCredit with strong Q1 result and good start into the year Result of EUR 33.5 million corresponds to a return on equity of 13.4% Loan portfolio grows by 3.0%, with good contribution from all segments Deposits grow by 2.8%; private clients as major driver in line with updated business strategy Net interest margin of 3...
EQS-News: Newron reports compelling additional data documenting the ef...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients 13.05.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change ...
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB sold after exercising options/sold 58,480 shares at 280.829SEK and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.